ABVX Abivax S.A.
QT22| Index | — | P/E | — | EPS (ttm) | -4.15 | Insider Own | — | Shs Outstand | 85.93M | Perf Week | -1.61% |
| Market Cap | 7.44B | Forward P/E | — | EPS next Y | -3.85 | Insider Trans | — | Shs Float | 79.31M | Perf Month | -8.95% |
| Enterprise Value | 6.97B | PEG | — | EPS next Q | -1.15 | Short Float | 9.15% | Perf Quarter | -30.61% | ||
| Income | -471.00M | P/S | — | EPS this Y | — | Short Ratio | 6.55 | Perf Half Y | -26.38% | ||
| Sales | 0.00 | P/B | 17.80 | EPS next Y | — | ROA | -76.32% | Short Interest | 7.25M | Perf YTD | -35.79% |
| Book/sh | 4.86 | P/C | 15.86 | EPS next 5Y | — | ROE | -85.88% | 52W High | 148.83 -42.95% | Perf Year | -12.48% |
| Cash/sh | 5.46 | P/FCF | — | EPS past 3/5Y | — | ROIC | -60.98% | 52W Low | 69.81 21.63% | Perf 3Y | 851.54% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | — | Volatility | 3.68% 4.14% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | — | ATR (14) | 4.05 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 5.97 | Sales Y/Y TTM | — | Profit Margin | — | RSI (14) | 40.03 | Recom | 2.08 |
| Dividend Gr. 3/5Y | — | Current Ratio | 5.97 | EPS Q/Q | -103.92% | SMA20 | -2.52% | Beta | 1.07 | Target Price | 156.50 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | -13.53% | Rel Volume | 0.77 | Prev Close | 86.59 |
| Employees | 80 | LT Debt/Eq | 0.00 | Earnings | Dec 21 | SMA200 | -24.11% | Avg Volume | 1.10M | Price | 84.91 |
| IPO Date | Oct 20, 2023 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -113.28% 69.09% | Net Debt/EBITDA | — | Volume | 842,193 | Change | -1.94% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-22-26 | Reiterated | Truist Securities | Buy | $155 → $151 |
| Sep-22-26 | Reiterated | Wedbush | Neutral | $90 → $118 |
| Sep-09-26 | Initiated | Goldman Sachs | Buy | $155 |
| Jul-24-26 | Reiterated | Morgan Stanley | Overweight | $132 → $180 |
| Jul-09-26 | Reiterated | Piper Sandler | Overweight | $142 → $175 |
| Jul-02-26 | Reiterated | Truist Securities | Buy | $135 → $155 |
| Jun-30-26 | Reiterated | BTIG | Buy | $150 → $175 |
| Jun-30-26 | Upgrade | Jefferies | Hold → Buy | $90 → $158 |
| Jun-03-26 | Reiterated | Wolfe Research | $176 → $136 | |
| Jun-02-26 | Reiterated | Morgan Stanley | Overweight | $145 → $132 |
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 63 | 82 | 42 | 31 | — | — | — | — | — | |
| Research and Development | 120 | 201 | 159 | 112 | — | — | — | — | — | |
| Other Operating Expense | 147 | -5 | -14 | -5 | — | — | — | — | — | |
| Operating Income | -330 | -278 | -187 | -138 | — | — | — | — | — | |
| Interest Expense | 19 | 32 | 13 | 15 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -123 | -63 | 10 | -7 | — | — | — | — | — | |
| Net Income Before Taxes | -472 | -373 | -191 | -160 | — | — | — | — | — | |
| Income Taxes | 0 | 7 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -471 | -379 | -191 | -160 | — | — | — | — | — | |
| Net Income From Continuing Operations | -471 | -379 | -191 | -160 | — | — | — | — | — | |
| Net Income | -471 | -379 | -191 | -160 | — | — | — | — | — | |
| EPS (Recurring) | -4.15 | -5.25 | -3.03 | -3.71 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.15 | -5.25 | -3.03 | -3.71 | — | — | — | — | — | |
| EPS (Diluted) | -4.15 | -5.25 | -3.03 | -3.71 | — | — | — | — | — | |
| EBITDA | -441 | -339 | -176 | -144 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 80 | 70 | 63 | 43 | — | — | — | — | — | |
| Market Capitalization | 6,793 | 9,440 | 461 | 460 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |